The advancement of drug development and tumor immunotherapy has spurred the emergence of numerous promising anti-tumor vaccines. These biological agents achieve personalized, low-toxicity tumor immunotherapy by activating or enhancing the body's specific immune response to tumor antigens, representing a crucial breakthrough in overcoming traditional treatment limitations. However, the high heterogeneity of tumors, complex immunosuppressive microenvironments, and host variability continue to pose multiple challenges for the development, optimization, and clinical translation of anti-tumor vaccines. To conduct in-depth and systematic research on the mechanisms of action of anti-tumor vaccines, researchers have constructed the Anti-Tumor Vaccine Database, an integrated scientific resource. This database comprehensively catalogs antitumor vaccines approved for market release or undergoing clinical trials worldwide, covering diverse vaccine types including peptides, viral vectors, genetically engineered vaccines, and personalized vaccines to meet therapeutic and research needs across multiple tumor types. Simultaneously, the database multidimensionally integrates key information including antigen composition, mechanisms of action, immunogenicity characteristics, clinical indications, and vaccination strategies. Through systematic organization and standardized presentation, this resource assists researchers in vaccine mechanism analysis, immune response profiling, and clinical efficacy evaluation. It further supports vaccine optimization design, combination therapy strategy development, and predictive biomarker discovery, propelling tumor immunotherapy toward precision and safety.
